Published in Rejuvenation Res on May 13, 2010
Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol (2012) 3.07
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch (2012) 1.15
Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS One (2011) 1.08
Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond) (2012) 1.04
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease. PLoS One (2011) 0.94
A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases. Front Endocrinol (Lausanne) (2013) 0.91
Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals (Basel) (2013) 0.88
Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice. J Alzheimers Dis (2013) 0.87
Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation. Neuropharmacology (2013) 0.86
Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation (2012) 0.86
The Angiotensin II Type 2 Receptor in Brain Functions: An Update. Int J Hypertens (2012) 0.85
Roles of Brain Angiotensin II in Cognitive Function and Dementia. Int J Hypertens (2012) 0.84
Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. Front Aging Neurosci (2014) 0.84
Intranasal administration of CNS therapeutics to awake mice. J Vis Exp (2013) 0.83
The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. PLoS One (2011) 0.83
siRNA Treatment: "A Sword-in-the-Stone" for Acute Brain Injuries. Genes (Basel) (2013) 0.81
Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun (2015) 0.79
Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients. Int J Clin Exp Med (2015) 0.78
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice. J Neurol Neurosurg (2015) 0.78
An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease. Alzheimers Res Ther (2016) 0.78
Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. Am J Transl Res (2012) 0.78
Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease. Cell Mol Neurobiol (2016) 0.78
Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34. PLoS One (2016) 0.76
Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies. PLoS One (2016) 0.76
Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy. Cell Mol Neurobiol (2016) 0.76
Effects of Lactobacillus plantarum TWK10-Fermented Soymilk on Deoxycorticosterone Acetate-Salt-Induced Hypertension and Associated Dementia in Rats. Nutrients (2016) 0.76
Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. Neurotherapeutics (2015) 0.76
Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia. Transl Psychiatry (2015) 0.75
Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathology. Alzheimers Res Ther (2016) 0.75
LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1(ΔE9) transgenic mice. Alzheimers Res Ther (2016) 0.75
Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep (2017) 0.75
Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications. Neurotox Res (2017) 0.75
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther (2013) 3.81
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Using trade names: a risk factor for accidental drug overdose. Arch Intern Med (2002) 2.91
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther (2004) 2.68
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci (2010) 2.65
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension (2004) 2.32
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 2.32
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem (2008) 2.24
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo. Clin Pharmacol Ther (2003) 2.08
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis (2008) 2.08
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics (2005) 1.95
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis (2010) 1.91
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ (2002) 1.88
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics (2007) 1.84
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem (2008) 1.84
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci (2008) 1.81
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med (2015) 1.68
Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem (2010) 1.66
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet (2007) 1.66
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther (2008) 1.62
Retracted Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain (2008) 1.60
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat (2003) 1.59
Ezetimibe and statin-associated myopathy. Ann Intern Med (2004) 1.58
Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 1.57
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics (2008) 1.52
Proximal femur fracture in older patients--rehabilitation and clinical outcome. Age Ageing (2003) 1.51
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res (2010) 1.49
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion (2007) 1.48
Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of Artemisia annua L. (annual wormwood). Am J Trop Med Hyg (2004) 1.43
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 1.42
Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am J Clin Nutr (2013) 1.41
Retracted Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states. Mol Pain (2012) 1.41
Vulnerability of the fetal primate brain to moderate reduction in maternal global nutrient availability. Proc Natl Acad Sci U S A (2011) 1.39
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics (2009) 1.36
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther (2004) 1.33
CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol (2004) 1.33
Pharmacogenomics of tamoxifen therapy. Clin Chem (2009) 1.31
Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet (2007) 1.31
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation (2008) 1.30
Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs (2013) 1.30
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol (2002) 1.28
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther (2003) 1.23
A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci U S A (2004) 1.23
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol (2008) 1.22
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res (2011) 1.21
Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol (2002) 1.21
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol (2005) 1.21
Glucocorticoid exposure at the dose used clinically alters cytoskeletal proteins and presynaptic terminals in the fetal baboon brain. J Physiol (2002) 1.19
Intranasal delivery of cells to the brain. Eur J Cell Biol (2009) 1.18
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res (2008) 1.17
Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun (2005) 1.17
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis (2009) 1.16
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int (2002) 1.15
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol (2005) 1.15
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics (2006) 1.14
Omics and drug response. Annu Rev Pharmacol Toxicol (2012) 1.14
Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci (2012) 1.14
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol (2013) 1.13
Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J Neurosci (2011) 1.13
Myopericytoma of the kidney. Hum Pathol (2010) 1.12
Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol (2011) 1.12
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One (2011) 1.12
Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. J Clin Invest (2013) 1.12
Mindfulness-based stress reduction for family caregivers: a randomized controlled trial. Gerontologist (2012) 1.12
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther (2006) 1.10
Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther (2009) 1.10
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics (2011) 1.09
Retracted Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes (2009) 1.09
Developmental pharmacokinetics. Handb Exp Pharmacol (2011) 1.09
Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain (2010) 1.09
A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol (2005) 1.07
Intranasal treatment of central nervous system dysfunction in humans. Pharm Res (2012) 1.07